Most Popular - A ravenous bull and bear community has developed around Peregrine Pharmaceuticals (NASDAQ:PPHM), and thus far, the bulls have scored big. The company answered most of … Continue Reading
Read nowQuick Picks - Shares of Zalicus Inc. (NASDAQ:ZLCS) sunk 40% before the open Monday morning after the company announced it would be discontinuing development of its Rheumatoid Arthritis … Continue Reading
Read nowMost Popular - Stem Cells Inc, (NASDAQ:STEM), developer of stem cell-based treatments for spinal injuries, is up for the second day in a row Friday in pre-market trading … Continue Reading
Read nowLong Ideas - Forest Laboratories (NYSE:FRX) and partner Ironwood Pharmaceuticals (NASDAQ:IRWD) announced FDA approval of Linzess (generically known as linaclotide) for the treatment of irritable bowel syndrome with … Continue Reading
Read nowQuick Picks - After Stifel Nicolaus initiated a Buy rating on Geron Corporation (NASDAQ:GERN) Thursday morning, shares are up 10% to $2.68. The $4 target price initially created … Continue Reading
Read nowLong Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) announced that the the only holder of its Class B shares had converted them all into Class A common stock on a … Continue Reading
Read nowLong Ideas - On Wednesday, the FDA removed Exelixis’ (NASDAQ:EXEL) lead candidate cabozantinib from the agenda of the Oncology Drugs Advisory Committee (ODAC) meeting in early November, but … Continue Reading
Read now